FindTrial
Sign In

Taxanes

DRUG5 trials

Sponsors

UNICANCER, Shanghai Jiao Tong University School of Medicine, Hebei Medical University Fourth Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

Advanced Breast CancerBrain MetastasesBreast CancerBreast NeoplasmHER2-positive Breast CancerMetastatic Breast Cancer

Phase 2

SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Active, not recruitingNCT02299999
UNICANCERMetastatic Breast Cancer
Start: 2014-04-07End: 2025-12-31Updated: 2025-01-15
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Active, not recruitingNCT04290793
Hebei Medical University Fourth HospitalBreast Cancer
Start: 2020-03-01End: 2026-12-10Target: 113Updated: 2026-01-07
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
NCT04760431
Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBrain Metastases, HER2-positive Breast Cancer
Start: 2021-10-01End: 2025-09-30Target: 120Updated: 2021-06-02

Phase 3

Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
Active, not recruitingNCT02455141
Shanghai Jiao Tong University School of MedicineBreast Neoplasm
Start: 2016-03-31End: 2030-03-31Updated: 2025-07-11

Phase 4

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).
RecruitingNCT06217185
Hebei Medical University Fourth HospitalAdvanced Breast Cancer, HER2-positive Breast Cancer
Start: 2024-01-02End: 2027-06-30Target: 100Updated: 2024-02-28

Related Papers

Abstract RF2-03: Adjuvant epirubicin plus cyclophosphamide followed by taxanes with or without carboplatin for early stage triple-negative breast cancer (RJBC 1501): a randomized controlled phase III trial
Clinical Cancer Research2026-02-17
Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts
Human Vaccines & Immunotherapeutics2025-04-243 citations
251P Genomic alterations of breast cancer patients with leptomeningeal disease: A retrospective analysis
ESMO Open2024-05-011 citations
Genomics to select treatment for patients with metastatic breast cancer.
2022-09-07119 citations
Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial.
Journal of Clinical Oncology2022-06-013 citations
Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
Genome Medicine2021-05-1853 citations
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.
2020-01-24221 citations
Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation
Cancer Research2019-07-012 citations
Abstract 4895: Natural history and outcome of patients presenting a metastatic breast cancer with PIK3CA mutation
Clinical Research (Excluding Clinical Trials)2019-07-01
An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity.
Journal of Clinical Oncology2018-05-205 citations
Treatment for Metastatic HER2 Breast Cancer Patients With High Loss of Heterozygosity
Oncology Times2017-08-04
Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study.
2016-11-0115 citations